Biologic therapy in inflammatory and immunomediated skin diseases: safety profile.

BIOLOGIC THERAPY IN INFLAMMATORY AND IMMUNOMEDIATED SKIN DISEASES: SAFETY PROFILE. Curr Drug Saf. 2015 Oct 14; Authors: Ganzetti G, Campanati A, Molinelli E, Offidani A Abstract Novel pathogenic aspects have recently emerged in many of the so-called immune-mediated inflammatory skin diseases and the biologic era have dramatically changed their therapeutic approach, leading clinicians to have a good control of both the disease and related comorbidities, with important impact on patient's quality of life. [1] Despite the use of biologics is well documented in the treatment of psoriasis and psoriatic arthritis, data on their off-label use in dermatology is mostly restricted to anecdotal cases, to case series or to retrospective data. [2] Randomized, controlled and double-blind clinical trials are lacking in literature, and there are no standardized guidelines, thus it is difficult to draft the efficacy and the safety profiles of their off-label use in dermatological diseases. [3] However, the rationale of the use of biologics in the treatment of various dermatological diseases relies on the blocking the effect of TNF-alpha, soluble in some cases and membrane and soluble in others, and the inflammatory cascade TNF-alpha-mediated. [4] The inhibition of TNF-alpha leads to apoptosis, reduces the recruitment of inflammatory cells in the tissues, promotes cytotoxicity and reduces angiogenesis. [5] As TNF-alpha, IL-12 and IL-23 are two inflamm...
Source: Current Drug Safety - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Saf Source Type: research